FDA Reauthorization Act aims to lower costs of ‘overpriced’ generic drugs

13:41 EDT 22 Aug 2017 | Healio

The long-term effects of the FDA Reauthorization Act of 2017 — signed into law by President Donald J. Trump on Monday — may include savings in drug-related Medicare expenses due to increased competition encouraged by the FDA by fast-tracking generic competitor approvals, according to an expert.“All things considered, this bill is mostly a good thing,” David Gortler, PharmD, FCCP, a professor of pharmacology and biotechnology at the George Washington School of Medicine & Health Sciences and a pharmacology and drug safety expert with the consulting group told “It has been praised by several long time FDA officials and seems to give the FDA more power in several areas. Even President Trump's most vigilant detractors will be hard-pressed to find faults with the FDA Reauthorization Act.”

Original Article: FDA Reauthorization Act aims to lower costs of ‘overpriced’ generic drugs


More From BioPortfolio on "FDA Reauthorization Act aims to lower costs of ‘overpriced’ generic drugs"

Quick Search


Relevant Topics

Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...